ES2150105T3 - Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso. - Google Patents

Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.

Info

Publication number
ES2150105T3
ES2150105T3 ES96904993T ES96904993T ES2150105T3 ES 2150105 T3 ES2150105 T3 ES 2150105T3 ES 96904993 T ES96904993 T ES 96904993T ES 96904993 T ES96904993 T ES 96904993T ES 2150105 T3 ES2150105 T3 ES 2150105T3
Authority
ES
Spain
Prior art keywords
pct
piretanida
sec
peak
piretanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96904993T
Other languages
English (en)
Inventor
Yuji Chikaraishi
Yoshihisa Matsuda
Makoto Otsuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP03321695A external-priority patent/JP3532988B2/ja
Priority claimed from JP03321595A external-priority patent/JP3532987B2/ja
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of ES2150105T3 publication Critical patent/ES2150105T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PIRETANIDA AMORFA QUE POSEE LAS CARACTERISTICAS SIGUIENTES: A) PICOS EXOTERMICOS A APROXIMADAMENTE 136{SUP,O}C Y APROXIMADAMENTE 209{SUP,O}C, B) UN PICO ENDOTERMICO A APROXIMADAMENTE 207{SUP,O}C, Y C) UN PUNTO DE FUSION DE APROXIMADAMENTE 225{SUP,O}C EN CURVAS TERMICAS DIFERENCIALES; D) UN PATRON DE HALO SIN PICO DE DIFRACCION (2{ZE}) EN ANALISIS DE DIFRACCION DE RAYOS X DE POLVO; Y E) ABSORCIONES CARACTERISTICAS HACIA 1700 CM{SUP,-1} Y 3200 DE INFRARROJO, Y QUE POSEE UNA SOLUBILIDAD SUPERIOR CERCA DE LA NEUTRALIDAD Y UNA ELEVADA BIODISPONIBILIDAD EFECTIVA EN FORMA DE ADMINISTRACION ORAL O INYECTADA, QUE SE PREPARA DISOLVIENDO PIRETANIDA EN UNA SOLUCION ACUOSA DE UNA BASE, AJUSTANDO EL VALOR DE PH DE LA SOLUCION CON UN ACIDO HASTA UN RANGO DE PH DESDE NO MENOS DE 3,87 HASTA NO MAS DE 4,37 Y RECUPERANDO EL PRECIPITADO QUE SE SEPARA DE ESTA FORMA, Y POLIMORFO DE PIRETANIDA QUE POSEE LAS CARACTERISTICAS SIGUIENTES: A) UN PICO ENDOTERMICO A APROXIMADAMENTE 132{SUP,O}C, B) UN PICO EXOTERMICO A APROXIMADAMENTE 143{SUP,O}C, Y C) UN PUNTO DE FUSION DE APROXIMADAMENTE 224{SUP,O}C EN CURVAS TERMICAS DIFERENCIALES; D) PICOS DE DIFRACCION (2{ZE}) A 10,5, 12,2, 15,6, 19,1, 19,9, 22,0, 22,8, 25,6, Y 30,6 EN ANALISIS DE DIFRACCION DE RAYOS X DE POLVO; Y E) ABSORCIONES CARACTERISTICAS HACIA 1700 CM{SUP-1} Y 3200 3500 CM{SUP,-1} EN EL ESPECTRO DE ABSORCION DE INFRARROJO, Y QUE POSEE UNA SOLUBILIDAD SUPERIOR CERCA DE LA NEUTRALIDAD Y UNA ELEVADA BIODISPONIBILIDAD EFECTIVA EN FORMA DE ADMINISTRACION ORAL O INYECTADA, QUE SE PREPARA DISOLVIENDO PIRETANIDA EN UNA SOLUCION ACUOSA DE UNA BASE, AJUSTANDO EL VALOR DE PH DE LA SOLUCION CON UN ACIDO HASTA UN RANGO DE PH DE MENOS DE 3,50 Y RECUPERANDO EL PRECIPITADO QUE SE SEPARA DE ESTA FORMA.
ES96904993T 1995-02-22 1996-02-12 Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso. Expired - Lifetime ES2150105T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP03321695A JP3532988B2 (ja) 1995-02-22 1995-02-22 ピレタニドの新規な結晶多形およびその製造方法
JP03321595A JP3532987B2 (ja) 1995-02-22 1995-02-22 新規な無晶形ピレタニドおよびその製造方法

Publications (1)

Publication Number Publication Date
ES2150105T3 true ES2150105T3 (es) 2000-11-16

Family

ID=26371876

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96904993T Expired - Lifetime ES2150105T3 (es) 1995-02-22 1996-02-12 Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.

Country Status (14)

Country Link
US (1) US6096779A (es)
EP (1) EP0812320B1 (es)
KR (1) KR100419355B1 (es)
CN (1) CN1072215C (es)
AT (1) ATE194607T1 (es)
BR (1) BR9607295A (es)
CA (1) CA2213693C (es)
DE (1) DE69609314T2 (es)
DK (1) DK0812320T3 (es)
ES (1) ES2150105T3 (es)
GR (1) GR3034605T3 (es)
MX (1) MX9706339A (es)
PT (1) PT812320E (es)
WO (1) WO1996026197A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
BRPI0311176B8 (pt) 2002-05-16 2021-05-25 Janssen Sciences Ireland Uc pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
EA011862B1 (ru) * 2004-03-24 2009-06-30 Актавис Груп Хф. Композиции рамиприла
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419970C3 (de) * 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
JPS5283547A (en) * 1976-01-01 1977-07-12 Hoechst Ag Tertiary cyclic amine
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
EP0243891B1 (en) * 1986-04-29 1991-08-14 Hoechst-Roussel Pharmaceuticals Incorporated A laminar structure for administering a chemical at a controlled release rate
EP0465841A3 (en) * 1990-06-13 1992-10-14 Hoechst Aktiengesellschaft Quick acting pharmaceutical inhalation forms of diuretics
JPH05230044A (ja) * 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形

Also Published As

Publication number Publication date
CN1072215C (zh) 2001-10-03
KR19980702374A (ko) 1998-07-15
DE69609314D1 (de) 2000-08-17
MX9706339A (es) 1998-07-31
CN1175948A (zh) 1998-03-11
WO1996026197A1 (en) 1996-08-29
PT812320E (pt) 2000-12-29
BR9607295A (pt) 1997-11-25
KR100419355B1 (ko) 2004-06-04
ATE194607T1 (de) 2000-07-15
CA2213693C (en) 2008-04-15
US6096779A (en) 2000-08-01
EP0812320B1 (en) 2000-07-12
EP0812320A1 (en) 1997-12-17
HK1006783A1 (en) 1999-03-19
DE69609314T2 (de) 2001-06-13
GR3034605T3 (en) 2001-01-31
CA2213693A1 (en) 1996-08-29
DK0812320T3 (da) 2003-04-14

Similar Documents

Publication Publication Date Title
AR056503A2 (es) SUSTANCIA MEDICINAL DE ARIPIRAZOL DE BAJA HIGROSCOPICIDAD Y PROCESO PARA LA PREPARACIoN DE LA MISMA
EG20218A (en) Process for preparing of substituted 3 aminoquinuclidines
AU7386594A (en) Perhydroisoindole derivatives as p substance antagonists
IL98163A0 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides,pharmaceuticals containing these compounds and their use
ATE259815T1 (de) Neue antagonistische verbindungen
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
AU2672995A (en) {a}-annelated pyrrole derivatives and pharmaceutical uses thereof
AU2797695A (en) Thiazolidine derivatives, their preparation and drugs containing same
MX13270A (es) Procedimiento para la preparacion de derivados de 4-aminopiridina
ES2150105T3 (es) Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.
AU4780285A (en) 1-substituted tetralin derivatives, their preparation and their use
ATE110365T1 (de) 2-alkyl-4-arylmethylaminochinoline, ihre verwendung und daraus hergestellte arzneimittel.
ZA983851B (en) Substituted 3,3-diamino-2-propenenitriles their preparation and use
AU582235B2 (en) Quinolylglycinamide derivatives,the process for preparation thereof and their therapeutic application as psychotropic drugs
FI885560A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
ZA949593B (en) N-substituted azabicycloheptane derivatives their preparation and use
NZ294878A (en) Water soluble derivatives of epipodophyllotoxin and medicaments
HUT53069A (en) Process for producing phenylhydrazones and pharmaceutical compositions and cosmetics comprising same
HUT77768A (hu) N-szubsztituált azabicikloheptánszármazékok, eljárás előállításukra és alkalmazásuk
BR7906217A (pt) Processo para a preparacao de derivados haologenados de i-azo-lil-i-fluorfenoxi-butano composicoes fungicidas e sua aplicacao
AR015190A1 (es) Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
EA199800364A1 (ru) Новая кристаллическая форма морфин-6-глюкуронида
YU6087A (en) Process for obtaining 2-benzimidazole-ilalkylthiosulphinyl or sulphonyl derivatives
IL108290A0 (en) Pyrrolidine derivatives, their preparation and medicaments containing them
TR199900013T2 (xx) Yeni bile�ikler.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 812320

Country of ref document: ES